Please note: The information displayed on this page might be outdated.
Confo Therapeutics: Confo Therapeutics is a pioneering biopharmaceutical company building a portfolio of best-in-class small molecule medicines for the treatment of orphan and rare diseases using its proprietary Confo® technology, a proprietary GPCR conformation-sensitive drug discovery engine.
GPCRs are a proven target class with a large untapped potential. The Confo® technology makes use of antibody fragments or “ConfoBodiesTM” to stabilize the cell membrane receptors in their functional conformation, revealing previously inaccessible structural features and providing a superior starting point for drug discovery.
In addition to developing its own pipeline, Confo Therapeutics has secured revenue-generating drug discovery partnerships with select leading pharma companies on GPCR targets which do not compete with its internal projects. The Company has ongoing collaborations with Lundbeck and Roche.

A private Company, Confo is backed by an international investor syndicate: BioGeneration Ventures, Capricorn Venture Partners, Fund+, MINTS, Perceptive Advisors, PMV, QBIC, V-Bio Ventures, VIB and Wellington Partners. Confo has raised a total of c. €40.3 million (both dilutive and non-dilutive funding) since it was spun out of Vrije Universiteit Brussel and VIB in 2015. The Company is headquartered in Ghent, Belgium and has laboratory facilities in Brussels (ConfobodyTM discovery), as well as Ghent (Drug Discovery).
Biotech Company
Based in...
Clinical Stage
Pre-Clinical Stage
Disease Space
Central Nervous System, Rare Disease
Europe, Private
Therapeutic Modalities
Platform Technology, Small Molecule
Technologiepark 94
Zwijnaarde, 9052

Company Participants at Private Company Showcase NYC 2019

  • Cedric Ververken, CEO